	US 12,214,078 B2
	Artificial beta cells and methods of use thereof
Zhen Gu, Los Angeles, CA (US); and Zhaowei Chen, Raleigh, NC (US)
Assigned to North Carolina State University, Raleigh, NC (US)
Filed by NORTH CAROLINA STATE UNIVERSITY, Raleigh, NC (US)
Filed on Jul. 13, 2022, as Appl. No. 17/812,254.
Application 17/812,254 is a continuation of application No. 16/648,026, granted, now 11,389,405, previously published as PCT/US2018/051310, filed on Sep. 17, 2018.
Claims priority of provisional application 62/559,909, filed on Sep. 18, 2017.
Prior Publication US 2023/0126077 A1, Apr. 27, 2023
Int. Cl. A61K 9/127 (2006.01); A61K 38/28 (2006.01); A61K 47/42 (2017.01)

CPC A61K 9/127 (2013.01) [A61K 38/28 (2013.01); A61K 47/42 (2013.01)]

20 Claims

1. A method of delivering a therapeutic agent to a subject comprising:

a. providing a particle comprising: an inner liposomal vesicle (ILV) encapsulating insulin or a biologically active compound derived from insulin; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent, wherein said membrane fusion-promoting agent selectively facilitates membrane fusion in response to changes in pH within the particle; and a pH-altering agent, wherein said pH-altering agent is a glucose-responsive enzyme inside the OLV but not inside an ILV;

b. triggering ILV and OLV fusion; and

c. releasing the insulin or biologically active compound derived from insulin outside of the OLV.